Nivolumab and ipilimumab population pharmacokinetics in support of pediatric dose recommendations—Going beyond the body‐size effect
Abstract Body size has historically been considered the primary source of difference in the pharmacokinetics (PKs) of monoclonal antibodies (mAbs) between children aged greater than or equal to 2 years and adults. The contribution of age‐associated differences (e.g., ontogeny) beyond body‐size diffe...
محفوظ في:
| المؤلفون الرئيسيون: | , , , , , , , |
|---|---|
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
Wiley
2024-03-01
|
| سلاسل: | CPT: Pharmacometrics & Systems Pharmacology |
| الوصول للمادة أونلاين: | https://doi.org/10.1002/psp4.13098 |
| الوسوم: |
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|